268 related articles for article (PubMed ID: 25633468)
1. Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study.
Buurman DJ; De Monchy JG; Schellekens RC; van der Waaij LA; Kleibeuker JH; Dijkstra G
Scand J Gastroenterol; 2015 Apr; 50(4):399-405. PubMed ID: 25633468
[TBL] [Abstract][Full Text] [Related]
2. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
3. [Two cases of drug-induced intrathoracic lesions caused by mesalazine in patients with ulcerative colitis].
Machida H; Shinohara T; Hatakeyama N; Inayama M; Hosokawa E; Ogushi F
Nihon Kokyuki Gakkai Zasshi; 2011 Jul; 49(7):538-42. PubMed ID: 21842693
[TBL] [Abstract][Full Text] [Related]
4. Mesalazine allergy in a boy with ulcerative colitis: clinical usefulness of mucosal biopsy criteria.
Wada S; Kumagai H; Yokoyama K; Ito T; Miyauchi A; Sakamoto S; Imagawa T; Tulyeu J; Tanaka M; Yamagata T
Clin J Gastroenterol; 2016 Oct; 9(5):302-5. PubMed ID: 27503129
[TBL] [Abstract][Full Text] [Related]
5. Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease.
Matsumoto S; Mashima H
Sci Rep; 2020 Dec; 10(1):22176. PubMed ID: 33335169
[TBL] [Abstract][Full Text] [Related]
6. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
Sun J; Yuan Y
Adv Ther; 2016 Mar; 33(3):400-9. PubMed ID: 26898569
[TBL] [Abstract][Full Text] [Related]
7. Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report.
Arai Y; Ogawa M; Yamane F; Sumiyoshi N; Arimoto R; Ando Y; Endo D; Nakada T; Sugawara I; Yokoyama H; Shimoyama K; Inomata H; Kawahara Y; Kato M; Arihiro S; Hokari A; Saruta M
Clin J Gastroenterol; 2020 Dec; 13(6):1200-1204. PubMed ID: 32880812
[TBL] [Abstract][Full Text] [Related]
8. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
10. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S; Doldo P; Ranzi T; Sturniolo GC; Giglio LA; Annese V; D'Arienzo A; Gaia E; Gullini S; Riegler G; Valentini M; Massa P; Del Piano M; Rossini F; Guidetti CS; Pera A; Greinwald R; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):677-84. PubMed ID: 10730559
[TBL] [Abstract][Full Text] [Related]
11. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M
Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857
[TBL] [Abstract][Full Text] [Related]
12. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
Richter JM; Kushkuley S; Barrett JA; Oster G
Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
[TBL] [Abstract][Full Text] [Related]
13. Acute interstitial nephritis due to mesalazine.
Tadic M; Grgurevic I; Scukanec-Spoljar M; Bozic B; Marusic S; Horvatic I; Galesic K
Nephrology (Carlton); 2005 Apr; 10(2):103-5. PubMed ID: 15877665
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
Miner PB; Wedel MK; Xia S; Baker BF
Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
[TBL] [Abstract][Full Text] [Related]
15. [A case of mesalazine-induced lung injury improved by only discontinuation of mesalazine].
Shimizu T; Hayashi M; Shimizu N; Kinebuchi S; Toyama J
Nihon Kokyuki Gakkai Zasshi; 2009 Jun; 47(6):543-7. PubMed ID: 19601534
[TBL] [Abstract][Full Text] [Related]
16. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
[TBL] [Abstract][Full Text] [Related]
17. Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis.
Michelini Z; Baroncelli S; Fantauzzi A; Pasquale C; Galluzzo CM; Sanchez M; Gatto M; Amici R; Franco M; d'Ettorre G; Fimiani C; Mezzaroma I; Vullo V; Merli M; Palmisano L
HIV Clin Trials; 2016 Mar; 17(2):49-54. PubMed ID: 26739837
[TBL] [Abstract][Full Text] [Related]
18. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
Raedler A; Behrens C; Bias P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
[TBL] [Abstract][Full Text] [Related]
19. [Induction of tolerance in hypersensitivity to mesalazine (5-ASA)].
Vázquez Fuertes L; Martínez-Cócera C; Robledo Echarren T; Domínguez Ortega J; González Gutiérrez ML
An Med Interna; 2005 Dec; 22(12):586-8. PubMed ID: 16454598
[TBL] [Abstract][Full Text] [Related]
20. Mesalazine-induced multi-organ hypersensitivity.
Sposato B; Allegri MP; Riccardi MP; Chigiotti S; Nencioni C; Ricciardi B; Carli T; Cresti A; Perari MG; Migliorini MG; Toti M
Clin Drug Investig; 2010; 30(6):413-7. PubMed ID: 20441247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
